AstraZeneca Plc (NYSE: AZN) reported a mix of clinical trial outcomes for its lung cancer treatments on Monday, achieving success in two late-stage studies while discontinuing a third due to missed primary endpoints.

The company secured favorable results for its targeted therapies in the SAFFRON and DESTINY-Lung04 Phase 3 trials. However, it halted the eVOLVE-Lung02 study after an independent review determined the treatment would likely fail to meet its dual primary endpoints in the specified patient cohort.

Favorable Results For Targeted Therapies

In the SAFFRON Phase 3 study, the combination of Tagrisso and Orpathys delivered a clinically meaningful and statistically significant extension in both overall survival and progression-free survival (PFS) against standard platinum-based chemotherapy.

The trial focused on patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) who experienced disease progression after earlier Tagrisso therapy. These patients exhibited high MET amplification or overexpression, a frequent resistance mechanism associated with a poor prognosis.

Orpathys is co-developed by AstraZeneca and Hutchmed Ltd (NASDAQ: HCM). The safety profile remained consistent with prior studies, and findings will be shared with global regulatory bodies.

Separately, the DESTINY-Lung04 Phase 3 trial yielded encouraging results for Enhertu as a primary treatment for unresectable, locally advanced, or metastatic HER2-mutant non-squamous NSCLC. The engineered antibody-drug conjugate, jointly developed with Daiichi Sankyo, demonstrated substantial PFS improvements over the global standard of care.

Discontinuation Of eVOLVE-Lung02 Study

AstraZeneca announced it is halting the eVOLVE-Lung02 Phase 3 trial. The study assessed volrustomig combined with chemotherapy as an initial therapy for metastatic NSCLC patients exhibiting PD-L1 expression below 50%.

Following a scheduled review, the Independent Data Monitoring Committee determined the combination would likely fall short of its dual primary endpoints in the PD-L1-negative patient cohort. Consequently, the trial is ending, though no unexpected safety signals emerged.

Other Phase 3 volrustomig evaluations targeting mesothelioma, cervical cancer, and head and neck squamous cell carcinoma will proceed as scheduled.

Market Reaction

AstraZeneca shares were up 0.20% at $156.76 during premarket trading on Monday, according to Benzinga Pro data.

AstraZeneca and Daiichi Sankyo announced positive high-level results from the DESTINY-Lung04 Phase III trial, marking a significant development in the treatment of non-small cell lung cancer. ENHERTU (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to the global standard of care. This makes it the first and only HER2-directed medicine to improve PFS over standard therapy in a Phase III trial for this specific patient population.

The trial evaluated ENHERTU as a first-line treatment for patients with unresectable, locally advanced or metastatic HER2-mutant non-squamous non-small cell lung cancer (NSCLC). The comparator arm consisted of platinum-pemetrexed doublet chemotherapy plus pembrolizumab, which represents the current global standard of care for these patients. Despite this robust combination therapy, many patients do not respond to first-line treatment and experience disease progression, highlighting the unmet need for more effective options.

Trial Context and Patient Population

Approximately 2-4% of patients with NSCLC have tumors with a HER2 mutation. For these individuals, the current standard of care involves a combination of immunotherapy and platinum-based chemotherapy. The DESTINY-Lung04 results suggest that targeting the HER2 mutation directly with ENHERTU offers a superior alternative in terms of delaying disease progression.

Next Steps

The trial will continue as planned to evaluate secondary endpoints, including overall survival. This ongoing data collection will provide further insight into the long-term efficacy and safety profile of ENHERTU in this patient group. The companies did not disclose specific numerical data for the hazard ratio or median PFS duration in this initial high-level announcement.

What the Numbers Show

While specific numerical outcomes were not disclosed, the characterization of the PFS improvement as both "statistically significant" and "clinically meaningful" indicates a robust separation between the treatment and control arms. Given that the standard of care already includes potent immunotherapy (pembrolizumab), achieving superiority over this benchmark suggests a strong mechanistic advantage for HER2-directed therapy in this specific molecular subset.